Recursion Pharmaceuticals (RXRX) Share-based Compensation (2020 - 2026)
Recursion Pharmaceuticals' (RXRX) quarterly Share-based Compensation came in at $22.2 million in Q1 2026, down 38.39% YoY from $36.1 million in Q1 2025, and down 75.56% on a QoQ basis from $90.9 million in Q4 2025.
Recursion Pharmaceuticals (RXRX) Share-based Compensation (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 6 years of Share-based Compensation data on file, last reported at $22.2 million in Q1 2026.
- Quarterly Share-based Compensation fell 38.39% year-over-year to $22.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $97.4 million (down 85.02% YoY) and the FY2025 annual result came in at $111.2 million, down 82.35% from the prior year.
- Share-based Compensation declined to $22.2 million in Q1 2026, from $90.9 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $630.1 million in Q4 2024 to a low of -$41.9 million in Q3 2025.
- A 5-year average of $48.1 million and a median of $16.1 million in 2023 frame the typical range for Share-based Compensation.
- The widest YoY moves for Share-based Compensation: up 3817.22% in 2024, down 294.44% in 2024.
- Tracing RXRX's Share-based Compensation over 5 years: stood at -$4.0 million in 2022, then soared by 507.24% to $16.1 million in 2023, then soared by 3817.22% to $630.1 million in 2024, then plunged by 85.57% to $90.9 million in 2025, then plunged by 75.56% to $22.2 million in 2026.
- The last three Share-based Compensation figures came in at $22.2 million (Q1 2026), $90.9 million (Q4 2025), and -$41.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn | 19.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19.50 Mn |
| Jun 30, 2026 | 19.50 Mn |
| Mar 31, 2026 | 22.22 Mn |
| Mar 31, 2026 | 22.22 Mn |
| Dec 31, 2025 | 90.91 Mn |
| Dec 31, 2025 | 90.91 Mn |
| Sep 30, 2025 | -41.90 Mn |
| Sep 30, 2025 | -41.90 Mn |
| Jun 30, 2025 | 26.16 Mn |
| Jun 30, 2025 | 26.16 Mn |
| Mar 31, 2025 | 36.06 Mn |
| Mar 31, 2025 | 36.06 Mn |
| Dec 31, 2024 | 630.12 Mn |
| Dec 31, 2024 | 630.12 Mn |
| Sep 30, 2024 | -32.65 Mn |
| Sep 30, 2024 | -32.65 Mn |
| Jun 30, 2024 | 16.52 Mn |
| Jun 30, 2024 | 16.52 Mn |
| Mar 31, 2024 | 16.13 Mn |
| Mar 31, 2024 | 16.13 Mn |